MSCO
Macau Society of Clinical Oncology
  • Twitter
  • Facebook
  • Home
  • Home
  • Oncology News
  • CME & EDUCATION
  • Research
  • MSCO Activities
  • Membership
  • About us

Aug 30 2018

Celastrol Induces Apoptosis in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells via Caspases-Dependent Pathways and Hsp90 Client Protein Degradation

Dr. Elaine LaiHan Leunget al reported that Celastrol Induces Apoptosis in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells via Caspases-Dependent Pathways and Hsp90 Client Protein Degradation   EGFR and KRAS mutations are the two most common driver mutations in non-small cell lung cancer (NSCLC). Molecular target-based therapy using small moleculessuch as gefitinib has been used for […]

Read More

By Yabing • Research • 0

Aug 26 2018

Monthly updates on NSCLC: Aug 2018

This article summaries recent progresses published in high impact journals on lung cancer research and treatment. Kindly provided by Ms. Dandan Hu (胡丹丹), a MSI from Roche China, will continually update for every month. Article in Chinese. JOURNAL OF CLINICAL ONCOLOGY Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer Published at jco.org […]

Read More

By Yabing • Oncology News • 0

Jul 3 2018

Celastrol Induces Apoptosis in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells via Caspases-Dependent Pathways

Dr. Elaine Lai-Han Leung et al reported a new compoundas apotential highly effectiveanti-cancer reagent in treatment of NSCLC . Our knowledge about molecular mechanisms for oncogene-driven tumors and about resistance to targeted therapies has increased quickly over the past year. As a result, several regulatory approvals of new agents that significantly improve survival and quality of life for […]

Read More

By Yabing • Uncategorized • 0

Jul 3 2018

Monthly updates of NSCLC: Issue June 2018

This article summaries recent progresses published in high impact journals on lung cancer research and treatment. Kindly provided by Ms. Dandan Hu (胡丹丹), a MSI from Roche China, will continually update for every month. Article in Chinese. THE NEW ENGLAND JOURNAL OF MEDICINE Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC Published at NEJM.org on […]

Read More

By Yabing • Oncology News • 0

19

Jul 3 2018

Travel to Moscow

作者係長期給網站供稿的美女胡丹丹 有些文明,兴盛于古代,却在近代没落,成为博物馆们竞相收藏的对象,展出令人赞叹,但观赏时不免悲怆;有些文明,在现代繁荣,但最多在工业革命之后才诞生,在教科书中被批判成资本主义原始掠夺的发家史……有一个民族,他十分特殊,似乎亘古强大:俄罗斯!他不仅仅是好战的军事强国,也在文学、艺术、体育上举世闻名。他有着多彩的文化,厚重的历史,2018年4月27日,我来了;2018年5月6日,我离开了,却一直心心念念他的好。 文艺之城莫斯科,艺术明珠圣彼得堡,谢谢让我有这样美好的旅行体验! 是因为红色革命的原因吗?还有本来就钟爱红色? 在莫斯科遇见了好多红色元素。 红场的2235米围墙、18座塔楼、5颗克林姆林宫红星、国家历史博物馆、圣瓦希里教堂,莫斯科河畔的红色十月巧克力工厂,都是厚厚的砖红色。 在俄罗斯必喝的红菜汤,连锁餐厅MyMy就有供应,价廉物美,如果不是很抗拒甜的话! (圣瓦西里教堂、红场、国家历史博物馆、巧克力工厂、连锁餐厅) 谢尔盖耶夫小镇,基督教东正教派的圣城麦加,莫斯科东北方向的金边小镇。 有谢尔盖耶夫圣三一修道院,拜占庭式的洋葱头教堂顶最为经典,各种颜色,十分鲜艳。建筑群初入眼帘的那一刻,惊喜! 神色、举止虔诚的信徒。进入教堂室内,信女都要先包裹好头巾。 也是玩具之乡,从画家手中入套娃一个。PS:不是餐厅的守门娃哦。 博物馆,最推荐: 特列季.亚科夫美术馆、俄罗斯国家博物馆互为补充,汇集了俄罗斯本国的艺术珍宝。我个人觉得是来俄罗斯最值得看的地方,独一无二。 (雕塑“第一步”;画作“伏尔加河上的纤夫”)   艾尔米塔什博物馆(冬宫)是全球四大博物馆之一,大名鼎鼎的叶卡捷琳娜二世女皇(也称大帝)是艺术品收藏的发起人和最大贡献者。馆藏丰富。 (冬宫广场、孔雀大钟)     卫国战争纪念馆是为纪念苏联1941-1945年卫国战争建造的。一楼是巨大的播放厅,播放时视频会打到整个屋顶和墙面,配上激情慷慨的俄语,十分震撼。还有讲述战争场面的巨幅油画。 (胜利广场、描绘胜利的油画)   另外,圣彼得堡本身就是一个大大的博物馆。涅瓦河畔、市区运河两岸古建筑林立,乘坐游船在大大小小的桥梁下穿行也别有一番味道。 民以食为天,到哪里都要寻访美食啊。 图兰朵,意大利歌剧中的中国蒙古公主,在莫斯科却是一个有着18世纪欧洲宫廷建筑风格、烧着欧亚两系菜的餐厅。全球十大之一?那另外9大是?看吧,知识就是这样,越了解,未知的边界就越大。 白兔餐厅,全球TOP50之23。伏特加配出的鸡尾酒也可以这样粉嫩甜美。 据说,普希金决斗前的最后一饮是黑咖啡配伏特加。第一杯正儿八经的伏特加,在圣彼得堡的普希金文学咖啡馆就这样喝掉了。 (白兔餐厅、普希金咖啡馆、图兰朵餐厅) 尽可能地多看些演出。 4月30日,芭蕾舞剧,舞姬 5月1日,芭蕾舞剧,安娜.卡列宁娜 5月2日,歌剧,茶花女 5月3日,芭蕾舞剧,宝石花 5月4日,多种艺术形式,仲夏夜之梦   在大理石宫的现代艺术展看到一句话,共勉:not in, but towards   永远期待下一次的旅行,去发现。 (作者是一個文青美女)

Read More

By Yabing • MSCO Activities • 0

May 22 2018

Monthly updates of NSCLC: Issue May 2018

This article summaries recent progresses published in high impact journals on lung cancer research and treatment. Kindly provided by Ms. Dandan Hu (胡丹丹), a MSI from Roche China, will continually update for every month. Article in Chinese.   THE NEW ENGLAND JOURNAL OF MEDICINE 本期未有文献入选。   JOURNAL OF CLINICAL ONCOLOGY Safety of Programmed Death–1 Pathway […]

Read More

By Yabing • Oncology News • 0

May 17 2018

Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations

Dr. Elaine Lai Han Leunget al reported that Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations    EGFR and KRAS mutations are the two most common driver mutations in non-small cell lung cancer (NSCLC). Molecular target-based therapy using small molecules such as Gefitinib has been used for inhibiting EGFR with good […]

Read More

By Yabing • News • 0

Apr 24 2018

Monthly updates of NSCLC: issue April 2018

This article summaries recent progresses published in high impact journals on lung cancer research and treatment. Kindly provided by Ms. Dandan Hu (胡丹丹), a MSI from Roche China, will continually update for every month. Article in Chinese. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer published on April 16,2018, at NEJM.org. NCT02259621,美国2期研究,旨在探索nivolumab +/- ipilimumab对于可切除NSCLC的新辅助治疗的价值。 本篇是对美国两家医学中心联合开展的预试验的分析。成人未治,手术可切除早期NSCLC(I/II/IIIA),术前给予2次PD-1抑制剂nivolumab治疗(3mg/kg/2周) ,首次给药后的4周左右开展手术治疗。首要终点为安全性和可行性。 […]

Read More

By Yabing • Oncology News • 0

Mar 29 2018

Suppressing mPGES-1 expression by sinomenine ameliorates inflammation and arthritis

Dr Elaine Lai-Han Leung et al reported that sinomenine suppresses inflammatory by inhibiting mPGES-1 expression. Microsomal prostaglandin E synthase 1 (mPGES-1) has attracted much attention from pharmacologists as a promising strategy and an attractive target for treating various types of diseases including rheumatoid arthritis (RA), which could preserve the anti-inflammatory effect while reducing the adverse […]

Read More

By Yabing • Oncology News • 0

Mar 21 2018

Monthly updates of NSCLC: issue March 2018

This article summaries recent progresses published in high impact journals on lung cancer research and treatment. Kindly provided by Ms. Dandan Hu (胡丹丹), a MSI from Roche China, will continually update for every month. Article in Chinese. THE NEW ENGLAND JOURNAL OF MEDICINE Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children N […]

Read More

By Yabing • Oncology News • 0

< 1 2 3 4 5 >»

Latest News

Latest News by MSCO

CME

Case Discussion

Event Calendar

Login

Register
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

↑

Copyright@MSCO. Macau Society of Clinical Oncology, 2017.